Drug profile · INN
edoxaban
LIXIANA
edoxaban (LIXIANA) is a coagulation factor x inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — edoxaban
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- ORAL
- Patents
- 20
- Programs
- 12
- Data quality
- 0.84
Quick answer
edoxaban (LIXIANA) is a coagulation factor x inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Coagulation factor X inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12415995
Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
granted -
US 12404315
Protease-activating CD45-gate CAR
granted -
US 12186368
Compositions and methods for treatment of protease mediated disease
granted -
US 12173337
Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 12077605
Cysteine protease inhibitors and methods of use thereof
granted -
US 12049505
Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
granted -
US 11918560
Serine protease inhibitor for treating coronavirus infection
granted -
US 11919880
HCV protease inhibitors
granted -
US 11891431
Removal of serine proteases by treatment with finely divided silicon dioxide
granted -
US 11872261
Lipoprotein targeting protease inhibitors and uses
granted -
US 11867695
Compositions and methods for detecting protease activity in biological systems
granted -
US 11866710
Transmembrane protease, serine 6 (TMPRSS6) iRNA compositions and methods of use thereof
granted -
US 11866407
Compositions and methods for inhibiting Mpro and PLpro protease activity and for preventing and treating SARS-CoV-2 infection
granted -
US 11834515
Macrocyclic compounds as proteasome inhibitors
granted -
US 11807882
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
granted -
US 11807646
4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)
granted -
US 11732005
Peptidomimetic proteasome inhibitors
granted -
US 11548944
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
granted -
US 11548943
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
granted -
US 11472875
Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
granted
Frequently asked questions
What is edoxaban?
edoxaban (LIXIANA) is a coagulation factor x inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for edoxaban?
LIXIANA is a marketed brand name for edoxaban. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of edoxaban?
edoxaban has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.